• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • SPORE In Prostate Cancer
    • External Funding Opportunities
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Clinical Trials

Clinical Trials

Clinical Trials

  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  1. Home
  2. Institute of Urologic Oncology
  3. Clinical Trials
  4. Fortis Study

A Study of FOR46 Given Every 21 Days for the Treatment of Your Prostate Cancer

Share this

Fortis Study

Lay Title: A study of FOR46 Given Every 21 days for the Treatment of Your Prostate Cancer

Technical Title: A Phase 1 Study of FOR46 Administered Every 21 Days in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Disease Type: Metastatic, castration-resistant prostate cancer

Basic information: The purpose of this study is to learn more about the safety and anticancer activity of the study drug, named FOR46, which is being developed to see if it can treat metastatic prostate cancer. FOR46 is made up of an antibody (a type of protein) and an anticancer drug. It is designed to travel through the bloodstream throughout the body and find cancer cells, and ultimately kill them or delay cancer growth. It is given to patients through the vein (intravenously, or IV).

Research Procedures (not a complete list): You will receive FOR46 on the first day of each 21-day treatment cycle. For the first two cycles, you will come to clinic several times per week the first week and once during the second week for other assessments, such as laboratory tests, cardiac tests, and eye exams. After the first two cycles, the study team will try to schedule your assessments to occur on the same day as your treatment.

Eligibility Criteria (not a complete list):

Inclusion Criteria:

  • Diagnosis of metastatic, castration-resistant prostate cancer (mCRPC)
  • Prostate cancer did not respond to at least one antiandrogen therapy (abiraterone, enzalutamide, or apalutamide) 

Exclusion Criteria:

  • No significant peripheral neuropathy or genetic disorders associated with peripheral neuropathy
  • No prior treatment with chemotherapy for mCRPC
  • No previous treatment with drugs targeting CD46, or with radium-223 (Xofigo) or other radiopharmaceuticals
  • No HIV; no active or chronic hepatitis B or C

For More Detailed Information, Contact:

  • Matthew Rettig, MD, Principal Investigator, Professor of UCLA Urology and UCLA Medicine in Hematology-Oncology
  • Sara R., Study Coordinator, (310) 794-2731

Read more about this study (NCT03575819) on ClinicalTrials.gov.

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest